The quarter missed on the only clean consensus metric. The published consensus was roughly a $0.32 loss per share with no revenue expected; Tango reported a $0.37 loss, a five-cent miss, while revenue was indeed $0.
| Metric | Q2 2026 | Q2 2025 / expectation | Read |
|---|---|---|---|
| Collaboration revenue | $0 | $3.2 million prior year; $0 expected | In line with the post-Gilead setup (Unaudited Consolidated Statements of Operations) |
| Research and development expense | $37.2 million | $32.8 million prior year | Higher as clinical programs advance (Unaudited Consolidated Statements of Operations) |
| General and administrative expense | $22.6 million | $11.3 million prior year | Sharp increase tied partly to personnel and stock compensation (Unaudited Consolidated Statements of Operations) |
| Net loss per share | $(0.37) | $(0.35) prior year; approximately $(0.32) consensus | Worse than expected (Unaudited Consolidated Statements of Operations) |
| Cash, cash equivalents and marketable securities | $1.0 billion | $343.1 million at December 31, 2025 | Provides substantial funding for the stated operating plan (Unaudited Consolidated Balance Sheets) |
The headline clinical result is confirmation, not a fresh surprise. The 92% objective response rate and 90% six-month progression-free survival rate for vopimetostat plus daraxonrasib had already been reported in June, so this filing mainly repeats those encouraging early-stage data rather than delivering a new readout (Clinical Pipeline Updates — Vopimetostat). The planned October 2026 ESMO presentation and work toward a Phase 3 design are meaningful next steps, but the registrational path remains under discussion with regulators and Revolution Medicines rather than finalized (Clinical Pipeline Updates — Vopimetostat; Upcoming Expected Milestones).
The company is visibly preparing for commercialization, but that also raises spending expectations. Appointing a chief commercialization officer and naming a new board chairman support Tango’s shift from research toward late-stage development and launch planning (Corporate Updates — Executive Leadership; Corporate Updates — Board of Directors). They do not yet change the probability of approval or provide a new commercial forecast, while general and administrative expense nearly doubled year over year (Unaudited Consolidated Statements of Operations).
Net: strategically on track, financially a little worse than expected. The strong cash balance reduces near-term financing pressure, and the pancreatic-cancer program remains the central value driver. But because the positive efficacy data were already known and the quarter produced no new clinical evidence or finalized Phase 3 plan, the filing does not add a comparable upside surprise to offset the five-cent EPS miss.
Read the original 8-K on SEC EDGAR ↗